News

Emsam was previously marketed and distributed by Bristol-Myers Squibb through a commercialization agreement. The transfer of distribution, marketing and sales to Dey concludes the three-year agreement with Bristol-Myers.

Debasish Roychowdhury, Senior Vice President and Head of Medicines Development at GlaxoSmithKline Oncology, said: The committee’s positive vote in support of ofatumumab is a potential milestone for patients

The FDA’s approval was based on the review of two clinical studies involving approximately 2000 kidney transplant recipients. A phase III, multi-center, open-label clinical trial was conducted where

Under the clinical trial, randomized and blinded study aims to determine the optimal dosage of both VE Patch and the H5N1 influenza vaccine injected concomitantly, when combined with

The trial aims to further build on data from the Phase III SHARP trial, which demonstrated that Nexavar significantly extended overall survival in patients with unresectable liver cancer

Following completion of the transaction, shares of the Irish company, Covidien plc, will begin trading on the New York Stock Exchange on June 5, 2009, under the symbol

The recommendation was provided on the basis of data provided from pivotal phase III trial of Sutent, compared to placebo. The result demonstrated that Sutent increased time to

Under the agreement, Sanofi Aventis will have a worldwide licence to XL147, an oral PI3K inhibitor, and XL765, an oral dual inhibitor of PI3K and mTOR. Both the

The settlement resolves the allegation that between 1995 and 2000, Aventis and its corporate predecessors knowingly misreported best prices for the steroid based anti inflammatory nasal sprays Azmacort,